IRLAB Therapeutics AB (OSTO:IRLAB A)
kr 3.165 -0.20 (-5.8%) Market Cap: 173.88 Mil Enterprise Value: 151.74 Mil PE Ratio: 0 PB Ratio: 37.68 GF Score: 29/100

Q1 2025 IRLAB Therapeutics AB Earnings Call Transcript

May 7, 2025 / 09:30 AM GMT
Release Date Price: kr7.08 (+9.97%)

Key Points

Positve
  • IRLAB Therapeutics AB (OSTO:IRLAB A) has five first-in-class candidates targeting Parkinson's disease, with three in clinical stages and two in preclinical stages.
  • The company received positive feedback from the EMA on the Mesdopetam program, enhancing its potential and value.
  • Positive results were achieved in the Phase 1 studies for IRL757, and a study in Parkinson's patients with apathy is planned.
  • The company has a strong patent portfolio, providing exclusivity well into the 2040s for its leading candidates.
  • IRLAB Therapeutics AB has secured funding for its IRL757 study through partnerships, ensuring financial support for ongoing research.
Negative
  • The Phase 2B trial for Pirepemat showed a reduction in fall rates, but the results were not statistically significant compared to placebo.
  • The company has decided to slow down the development pace for IRL942 to focus resources on more critical activities.
  • IRLAB Therapeutics AB's cash position includes SEK 58 million in prepayments, which limits available funds for other projects.
  • The company is actively seeking partners for its late-stage candidates, indicating a reliance on external collaborations for market entry.
  • There is an increased focus on cost control, suggesting financial constraints that may impact future research and development activities.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

IRLABa.ST - IRLAB Therapeutics AB
Q1 2025 IRLAB Therapeutics AB Earnings Call
May 07, 2025 / 09:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to this live broadcast at Q1 presentation by research company I Lab Therapeutics. Presenting today is CEO Christina Torvko, executive Vice President of Research and Development Nicholas Waters, and CEO Victor Sivich.

After the presentation, there will be a Q&A session with equity analysts and viewers can ask their questions in the live chat.

Hello and welcome Christina Toro.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Hello, and thank you very much.

--------------------------------------------------------------------------------
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot